15-Sep-14 10:00 AM  CST

Food and Drug Administration Approves Weight Loss Drug Contrave

According to the Centers for Disease Control (CDC), more than 78.6 million adults in the United States are overweight. Obesity can increase the chances of heart-disease, heart-attacks, strokes, high blood pressure, type 2 diabetes, and many other health conditions. Recently, the Food and Drug Administration (FDA) approved Contrave (naltrexone hydrochloride and bupropion hydrochloride) as a pharmaceutical weight loss option.

            Contrave is approved for adults with a BMI (body mass index) of 30 or greater and BMI of 27 or greater who have at least one weight related health condition of high blood pressure, type 2 diabetes, or elevated cholesterol.  Contrave is unique in that it contains naltrexone, which is approved to treat alcohol and opioid dependence, and bupropion, which is approved to treat depression, anxiety, seasonal affective disorder (SAD), and used as a smoking cessation treatment.

            The FDA recommends that patients be evaluated after 12 weeks of treatment in patients using the maintenance dose. Blood pressure and pulse should be monitored throughout the treatment as well.  Contrave comes with a black boxed warning to be sure patients and healthcare professionals are aware of the increased risk of suicidal thoughts and neuropsychiatric events. Contrave should not be used in patients that have seizure disorders. It should also be noted that Contrave can also raise blood pressure and heart rate.

            Jean-Marc Guettier, M.D., and Director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research, recently commented on the drugs approval. “When used as directed in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, Contrave provides another treatment option for chronic weight management for people who are obese or are overweight and have at least one weight-related health condition,” said Guettier.

            The risks and benefits of using Contrave should be discussed with the patient’s doctor to decide if Contrave is right for them. More breaking news in the pharmaceutical field can be found by going to www.pharmacytechnician.org.

 

 

Sources:

1. Liscinsky, Morgan. “FDA Approves Weight-Management Drug Contrave.” FDA Press Release. Web. Date of Access: 15 Sept 2014. 

2. Chavis, Ryan. “FDA Approves Contrave For Weight Management.” Drug Store News. Web. Date of Access: 15 Sept 2014. 

3. CDC Facts Sheet.  “Adult Obesity Facts.” CDC.gov. Web. Date of Access: 15 Sept 2014. 


For additional information on this article, please contact:
 
 
Source: Jennifer S. O’Reilly  

Tendenci™ User Home © 2004 Tendenci™ software by Schipul - "The Web Marketing Company" | www.schipul.com